AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
58 hedge funds and large institutions have $79M invested in AVEO Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 9 closing their positions.
408% more call options, than puts
Call options by funds: $3.34M | Put options by funds: $657K
9% more capital invested
Capital invested by funds: $72.3M → $79M (+$6.65M)
0% more funds holding
Funds holding: 58 → 58 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.09M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$956K |
| 3 |
Millennium Management
New York
|
+$637K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$494K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.04M |
| 2 |
Goldman Sachs
New York
|
-$1M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$878K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$579K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$463K |
AVEO Hedge Fund Activity: Q1 2022 in Review
58 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2022, worth a combined $79M — up 9.2% from $72.3M a quarter earlier.
Fund positioning in AVEO was balanced in Q1 2022: 9 funds opened new positions, 9 closed out, 13 added to existing stakes and 15 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.09M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $7.04M sold.
- 58 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $79M of AVEO Pharmaceuticals, Inc. stock for Q1 2022, up 9.2% quarter-over-quarter.
- 9 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2022 and 9 closed out, a net change of 0 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2022 was AIGH Capital Management, an estimated $1.09M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2022 was Adage Capital Partners, an estimated $7.04M sold.
Based on aggregated 13F filings for Q1 2022.